Abstract
Tolvaptan, a selective vasopressin V2-receptor antagonist, has clinical efficacy in reducing volume overload in patients with heart failure. However, it is still unclear whether Tolvaptan improves long-term prognos is or not. In this study, we investigated the long-term effect of Tolvaptan in patients with diuretic-resistant heart failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
